An experimental drug drove people to lose 23% of their body weight. It’s still seen as a disappointment
By Meg Tirrell, CNN (CNN) — Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more effective medicines to turbo-charge diabetes and weight-loss results with the class known as GLP-1 receptor agonists. Novo
Continue Reading